Cordycepin prevented IL-β-induced expression of inflammatory mediators in human osteoarthritis chondrocytes

International Orthopaedics

Volumn 38, Issue 7, 2014, Pages 1519-1526

  Ying, Xiaozhou ^a   Peng, Lei ^b   Chen, Hua ^a   Shen, Yue ^a   Yu, Kehe ^a   Cheng, Shaowen ^b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b HAINAN MEDICAL UNIVERSITY   (China)

Author keywords

Cordycepin; Interleukin 1 (IL 1 ); Nitric oxide; Osteoarthritis

Indexed keywords

ANTIINFLAMMATORY AGENT; COLLAGENASE 3; CORDYCEPIN; CYCLOOXYGENASE 2; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRIC OXIDE; NITRITE; PROSTAGLANDIN E2; DEOXYADENOSINE DERIVATIVE;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARTILAGE CELL; CASE REPORT; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; CYTOPLASM; CYTOTOXICITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; DRUG EFFECTS; METABOLISM; MIDDLE AGED;

AGED; ANTI-INFLAMMATORY AGENTS; CHONDROCYTES; DEOXYADENOSINES; FEMALE; HUMANS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; OSTEOARTHRITIS;

EID: 84903543394     PISSN: 03412695     EISSN: 14325195     Source Type: Journal    
DOI: 10.1007/s00264-013-2219-4     Document Type: Article

References (36)

1. Flugge LA, Miller-Deist LA, Petillo PA (1999) Towards a molecular understanding of arthritis. Chem Biol 6(6):R157-166. doi:10.1016/s1074-5521(99) 80043-x (Pubitemid 29363164)
2. Goldring MB, Otero M, Tsuchimochi K, Ijiri K, Li Y (2008) Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism. Ann Rheum Dis 67(Suppl 3):iii75-82. doi:10.1136/ard.2008.098764
3. Loeser RF (2006) Molecular mechanisms of cartilage destruction: mechanics, inflammatory mediators, and aging collide. Arthritis Rheum 54(5):1357-1360. doi:10.1002/art.21813
4. Pelletier JP, Martel-Pelletier J, Abramson SB (2001) Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 44(6):1237-1247. doi:10.1002/1529-0131(200106)44: 6<1237::aid-art214>3.0.co;2-f (Pubitemid 32537520)
5. Kobayashi M, Squires GR, Mousa A, Tanzer M, Zukor DJ, Antoniou J, Feige U, Poole AR (2005) Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum 52(1):128-135. doi:10.1002/art.20776 (Pubitemid 40129241)
6. Goldring SR, Goldring MB (2004) The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res 427 Suppl:S27-36 (Pubitemid 39362798)
7. Pelletier JP, Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, Fernandes JC, Martel-Pelletier J (1997) In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 40(6):1012-1019. doi:10.1002/1529-0131(199706)40: 6<1012::AID-ART3>3.0.CO;2-# (Pubitemid 27242287)
8. Han ES, Oh JY, Park HJ (2011) Cordyceps militaris extract suppresses dextran sodium sulfate-induced acute colitis in mice and production of inflammatory mediators from macrophages and mast cells. J Ethnopharmacol 134(3):703-710. doi:10.1016/j.jep.2011.01.022
9. Hubbell HR, Pequignot EC, Willis DH, Lee C, Suhadolnik RJ (1985) Differential antiproliferative actions of 2′,5′ oligo A trimer core and its cordycepin analogue on human tumor cells. Int J Cancer 36(3): 389-394 (Pubitemid 16251005)
10. Won SY, Park EH (2005) Anti-inflammatory and related pharmacological activities of culturedmycelia and fruiting bodies of Cordyceps militaris. J Ethnopharmacol 96(3):555-561. doi:10.1016/j.jep.2004.10.009
11. Lee HH, Jeong JW, Lee JH, Kim GY, Cheong J, Jeong YK, Yoo YH, Choi YH (2013) Cordycepin increases sensitivity of Hep3B human hepatocellular carcinoma cells to TRAIL-mediated apoptosis by inactivating the JNK signaling pathway. Oncol Rep. doi:10.3892/or.2013.2589
12. Sjoholm A, Nystrom T (2005) Endothelial inflammation in insulin resistance. Lancet 365(9459):610-612. doi:10.1016/s0140-6736(05)17912-4 (Pubitemid 40247919)
13. Yoo HS, Shin JW, Cho JH, Son CG, Lee YW, Park SY, Cho CK (2004) Effects of Cordyceps militaris extract on angiogenesis and tumor growth. Acta Pharmacol Sin 25(5):657-665
14. Kan WC, Wang HY, Chien CC, Li SL, Chen YC, Chang LH, Cheng CH, Tsai WC, Hwang JC, Su SB, Huang LH, Chuu JJ (2012) Effects of Extract from Solid-State Fermented Cordyceps sinensis on Type 2 Diabetes Mellitus. Evid Based Complement Alternat Med 2012: 743107. doi:10.1155/2012/743107
15. Li L, He D, Yang J, Wang X (2011) Cordycepin inhibits renal interstitial myofibroblast activation probably by inducing hepatocyte growth factor expression. J Pharmacol Sci 117(4): 286-294
16. Noh EM, Kim JS, Hur H, Park BH, Song EK, Han MK, Kwon KB, Yoo WH, Shim IK, Lee SJ, Youn HJ, Lee YR (2009) Cordycepin inhibits IL-1beta-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts. Rheumatology (Oxford) 48(1): 45-48. doi:10.1093/rheumatology/ken417
17. Shin S, Lee S, Kwon J, Moon S, Lee CK, Cho K, Ha NJ, Kim K (2009) Cordycepin Suppresses Expression of Diabetes Regulating Genes by Inhibition of Lipopolysaccharide-induced Inflammation in Macrophages. Immune Netw 9(3):98-105. doi:10.4110/in.2009.9.3.98
18. Baik JS, Kwon HY, Kim KS, Jeong YK, Cho YS, Lee YC (2012) Cordycepin induces apoptosis in human neuroblastoma SK-NBE(2)-C and melanoma SK-MEL-2 cells. Indian J Biochem Biophys 49(2):86-91
19. Jeong MH, Seo MJ, Park JU, Kang BW, Kim KS, Lee JY, Kim GY, Kim JI, Choi YH, Kim KH, Jeong YK (2012) Effect of cordycepin purified from Cordyceps militaris on Th1 and Th2 cytokines in mouse splenocytes. J Microbiol Biotechnol 22(8):1161-1164
20. Lee HJ, Burger P, Vogel M, Friese K, Bruning A (2012) The nucleoside antagonist cordycepin causes DNA double strand breaks in breast cancer cells. Investig New Drugs 30(5):1917-1925. doi:10.1007/s10637-012-9859-x
21. Liu Q, Hong IP, Ahn MJ, Yoo HS, Han SB, Hwang BY, Lee MK (2011) Anti-adipogenic activity of Cordyceps militaris in 3 T3-L1 cells. Nat Prod Commun 6(12):1839-1841
22. Wu CW, Morrell MR, Heinze E, Concoff AL, Wollaston SJ, Arnold EL, Singh R, Charles C, Skovrun ML, FitzGerald JD, Moreland LW, Kalunian KC (2005) Validation of American College of Rheumatology classification criteria for knee osteoarthritis using arthroscopically defined cartilage damage scores. Semin Arthritis Rheum 35(3):197-201. doi:10.1016/j.semarthrit.2005.06.002 (Pubitemid 41713959)
23. Ying X, Cheng S, Shen Y, Cheng X, An Rompis F, Wang W, Lin Z, Chen Q, Zhang W, Kou D, Peng L, Tian XQ, Lu CZ (2012) Nicotine promotes proliferation and collagen synthesis of chondrocytes isolated from normal human and osteoarthritis patients. Mol Cell Biochem 359(1-2):263-269. doi:10.1007/s11010- 011-1020-1
24. Ying X, Chen X, Cheng S, Shen Y, Peng L, Xu HZ (2013) Piperine inhibits IL-beta induced expression of inflammatory mediators in human osteoarthritis chondrocyte. Int Immunopharmacol. doi:10.1016/j.intimp.2013.06.025
25. Akhtar N, Miller MJ, Haqqi TM (2011) Effect of a Herbal-Leucine mix on the IL-1beta-induced cartilage degradation and inflammatory gene expression in human chondrocytes. BMC Complement Altern Med 11:66. doi:10.1186/1472-6882-11-66
26. Kim KS, da Oh H, Choi HM, Bang JS, Ryu CJ, Kim JH, Yoo MC, Yang HI (2009) Pyrrolidine dithiocarbamate, a NF-kappaB inhibitor, upregulates MMP-1 and MMP-13 in IL-1beta-stimulated rheumatoid arthritis fibroblast-like synoviocytes. Eur J Pharmacol 613(1-3):167-175. doi:10.1016/j.ejphar.2009.04.026
27. Wei XQ, Charles IG, Smith A, Ure J, Feng GJ, Huang FP, Xu D, Muller W, Moncada S, Liew FY (1995) Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 375(6530):408-411. doi:10.1038/375408a0
28. Heard BJ, Martin L, Rattner JB, Frank CB, Hart DA, Krawetz R (2012) Matrix metalloproteinase protein expression profiles cannot distinguish between normal and early osteoarthritic synovial fluid. BMC Musculoskelet Disord 13:126. doi:10.1186/1471-2474-13-126
29. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, Geoghegan KF, Hambor JE (1996) Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 97(3):761-768. doi:10.1172/jci118475 (Pubitemid 26060542)
30. Little CB, Barai A, Burkhardt D, Smith SM, Fosang AJ, Werb Z, Shah M, Thompson EW (2009) Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum 60(12):3723-3733. doi:10.1002/art.25002
31. Flannery CR, Little CB, Hughes CE, Curtis CL, Caterson B, Jones SA (2000) IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage. Matrix Biol 19(6):549-553
32. Tak PP, Firestein GS (2001) NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107(1):7-11. doi:10.1172/jci11830 (Pubitemid 32047405)
33. Gilston V, Jones HW, Soo CC, Coumbe A, Blades S, Kaltschmidt C, Baeuerle PA, Morris CJ, Blake DR, Winyard PG (1997) NF-kappa B activation in human knee-joint synovial tissue during the early stage of joint inflammation. Biochem Soc Trans 25(3):518S (Pubitemid 27417126)
34. Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, Stimpson SA, Baldwin AS, Makarov SS (1998) NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci U S A 95(23):13859-13864 (Pubitemid 28523063)
35. Lu HT, Liang YC, Sheu MT, Ho HO, Lin YT, Hsieh MS, Chen CH (2008) Disease-modifying effects of glucosamine HCl involving regulation of metalloproteinases and chemokines activated by interleukin-1beta in human primary synovial fibroblasts. J Cell Biochem 104(1):38-50. doi:10.1002/jcb.21597
36. Ren Z, Cui J, Huo Z, Xue J, Cui H, Luo B, Jiang L, Yang R (2012) Cordycepin suppresses TNF-alpha-induced NF-kappaB activation by reducing p65 transcriptional activity, inhibiting IkappaBalpha phosphorylation, and blocking IKKgamma ubiquitination. Int Immunopharmacol 14(4):698-703. doi:10.1016/j. intimp.2012.10.008